Apraglutide is a medication being studied for patients with Short Bowel Syndrome with Intestinal Failure (SBS-IF). It belongs to a class of drugs called GLP-2 analogues that help improve intestinal absorption. The medication works by helping the intestines better absorb nutrients and fluids from food, which is particularly important for patients who have lost part of their intestines. It is designed to be used as a long-term treatment to help manage the symptoms and complications of Short Bowel Syndrome.

Short Bowel Syndrome – A condition that occurs when part of the small intestine is missing or has been surgically removed, resulting in the body’s reduced ability to absorb nutrients from food. The condition leads to problems with maintaining proper nutrition and hydration because the remaining intestine cannot absorb enough water, vitamins, and other nutrients from food. People with this condition may experience diarrhea, fatigue, and weight loss. The severity of symptoms depends on which sections and how much of the small intestine are affected. The body may gradually adapt to the shorter bowel over time, though some people may need ongoing nutritional support.